0000000000135698

AUTHOR

Maria Pia Foschino

showing 3 related works from this author

Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study

2019

BACKGROUND: Small airways dysfunction (SAD) is well recognised in asthma, yet its role in the severity and control of asthma is unclear. This study aimed to assess which combination of biomarkers, physiological tests, and imaging markers best measure the presence and extent of SAD in patients with asthma.METHODS: In this baseline assessment of a multinational prospective cohort study (the Assessment of Small Airways Involvement in Asthma [ATLANTIS] study), we recruited participants with and without asthma (defined as Global Initiative for Asthma severity stages 1-5) from general practices, the databases of chest physicians, and advertisements at 29 centres across nine countries (Brazil, Chi…

Pulmonary and Respiratory MedicineSpirometrymedicine.medical_specialtySocio-culturaleSettore MED/10 - Malattie Dell'Apparato RespiratorioDISEASE03 medical and health sciences0302 clinical medicineQuality of lifeHYPERRESPONSIVENESSInternal medicineSeverity of illnessMedicine030212 general & internal medicineProspective cohort studyAsthmamedicine.diagnostic_testbusiness.industryasthmamedicine.diseaseNitrogen washoutrespiratory tract diseasessmall airways dysfunctionLUNG-MECHANICSSEVERITY030228 respiratory systemSalbutamolVENTILATION HETEROGENEITYbiomarkerAsthma; small airways dysfunctionbusinessmedicine.drugCohort study
researchProduct

The Severe Asthma Network in Italy: Findings and Perspectives

2019

Background Severe Asthma Network in Italy (SANI) is a registry of patients recruited by accredited centers on severe asthma. Objective To analyze epidemiological, clinical, inflammatory, functional, and treatment characteristics of severe asthmatics from the SANI registry. Methods All consecutive patients with severe asthma were included into the registry, without exclusion criteria to have real-life data on demographics, asthma control, treatments (including biologics), inflammatory biomarkers, and comorbidities. Results A total of 437 patients (mean age: 54.1 years, 57.2% females, 70.7% atopics, 94.5% in Global Initiative for Asthma severity step V) were enrolled into the study. The mean …

AdultMalemedicine.medical_specialtyRegistrySevere asthmaExacerbationBronchiectasis; Comorbidities; Late-onset asthma; Nasal polyps; Registry; SANI; Severe asthma; Immunology and AllergyOmalizumabComorbiditySettore MED/10 - Malattie Dell'Apparato RespiratorioComorbiditiesAtopy03 medical and health sciencesBronchiectasi0302 clinical medicineFood allergyInternal medicineLate-onset asthmaNasal polypsBronchiectasis; Comorbidities; Late-onset asthma; Nasal polyps; Registry; SANI; Severe asthma; Adult; Aged; Asthma; Bronchiectasis; Comorbidity; Eosinophils; Female; Humans; Immunoglobulin E; Italy; Male; Middle Aged; Nasal Polyps; Registries; RhinitisMedicineHumansBronchiectasis Comorbidities Late-onset asthma Nasal polyps Registry SANI Severe asthma Immunology and AllergyImmunology and Allergy030212 general & internal medicineRegistriesAsthmaAgedRhinitisBronchiectasisbusiness.industryNasal polypSANIImmunoglobulin EMiddle Agedmedicine.diseaseAsthmaBronchiectasisEosinophils030228 respiratory systemItalyAsthma Control QuestionnaireFemaleComorbiditiebusinessMepolizumabmedicine.drug
researchProduct

Adherence to omalizumab: A multicenter “real-world” study

2020

Background: Adherence to medications is crucial in patients with severe asthma in light of the negative clinical impact and costs of non-adherence. Adherence to omalizumab has not been well studied in real-world settings. The aim of this study was to assess adherence to omalizumab and evaluate treatment effectiveness in relation to adherence. Methods: This was a retrospective, observational, and multicenter real-world study. Omalizumab dose, timing of administration, and duration of treatment ( 4 years) were analyzed. Adherence was evaluated by examining rates of expected and missing doses. Good adherence (10% doses missed) were determined. For effectiveness in relation to adherence of omal…

lcsh:Immunologic diseases. AllergyPulmonary and Respiratory Medicinemedicine.medical_specialtySevere asthmaEfficacySevere asthmaImmunologyOmalizumabOmalizumabSettore MED/10 - Malattie Dell'Apparato RespiratorioArticlePoor adherence03 medical and health sciences0302 clinical medicineInternal medicineImmunology and AllergyMedicineIn patient030223 otorhinolaryngologyAsthmaAsthma exacerbationsbusiness.industrySevere asthma Omalizumab Adherence Efficacy Real-worldmedicine.disease030228 respiratory systemReal-worldAdherenceObservational studylcsh:RC581-607businessAsthma Control Testmedicine.drug
researchProduct